To quantify the relationship between weight loss and blood pressure reduction could help clinicians to refine treatment targets and better understand the cardiovascular effects of contemporary anti-obesity medicines
Last updated on Oct 16, 2025
The Risks and Side Effects of GLP-1 RA All medications come with certain risks and side effects and GLP-1 RAs are no different
The risk of fake or contaminated products is real
Understanding the nuances of this treatment and its role within a larger health plan is essential before beginning therapy
GLP-1 effects in certain areas of the brain ultimately lead to weight loss, and in addition to the cardioprotective and renoprotective effects discussed in this article, evidence also points towards neuroprotective and other medically desirable properties ( FIGURE 1 Currently, two main classes of GLP-1 RAs are available ( In accordance with their mechanism of action, all marketed GLP-1 RAs are indicated to improve glycaemic control in people with type 2 diabetes ( Epidemiology and pathophysiology of heart failure As one of the most prevalent consequences of CVD and other cardiometabolic conditions such as diabetes and hypertension, HF remains associated with high mortality rates ( As outlined earlier, cardiometabolic diseases or risk factors such as type 2 diabetes (ClinicalTrials.gov IDs NCT04916470 and NCT04788511), it may be relevant to consider obesity-related HFpEF as a specific (sub)phenotype, whether coexisting with type 2 diabetes or not
